Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is focused on oncology and have engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Its immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes; and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization. The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

Seattle, US
Size (employees)
50 (est)
Immune Design was founded in 2008 and is headquartered in Seattle, US
Report incorrect company information

Immune Design Office Locations

Immune Design has an office in South San Francisco and Seattle
Seattle, US (HQ)
310 1616 Eastlake Ave E
South San Francisco, US
250 601 Gateway Blvd
Show all (2)
Report incorrect company information

Immune Design Financials and Metrics

Immune Design Financials

Market capitalization (5-Feb-2018)

85.8 m
Immune Design's current market capitalization is $85.8 m.
Show all financial metrics

Immune Design Operating Metrics

FY, 2016

Patents (US)


Patents (foreign)


Phase I Trials


Phase II Trials

Show all operating metrics
Report incorrect company information